Fluorine-18 fluorodeoxyglucose positron emission tomography (PET) to detect vital retinoblastoma in the eye: Preliminary experience

Moll, AC; Hoekstra, Otto S.; Imhof, S.M.; Comans, E. F. I.; Meeteren, A.Y.N. Schouten-van; Valk, P. van der; Boers, Maarten

doi:10.1076/opge.25.1.31.29001

Cited by 24 publications

(14 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They opined that 18 F-FDG PET may not have a role in retinoblastoma (6). In our study, 5 of 25 patients had bilateral retinoblastoma, with IRSS stage III retinoblastoma in one eye and intraocular retinoblastoma in the opposite eye.…”

Section: Discussionmentioning

confidence: 80%

“…To the best of our knowledge, the role of 18 F-FDG PET/CT in retinoblastoma has not been reported in the published literature. There has been only 1 previous report on the use of 18 F-FDG PET alone without CT in 4 patients with retinoblastoma (6). In developing countries, 25%-40% of all retinoblastoma patients belong to IRSS stage III, because of delayed presentation and diagnosis (7,8).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Role of PET/CT in Staging and Evaluation of Treatment Response After 3 Cycles of Chemotherapy in Locally Advanced Retinoblastoma: A Prospective Study

Radhakrishnan¹,

Kumar²,

Malhotra³

et al. 2012

J Nucl Med

View full text Add to dashboard Cite

The present study prospectively evaluated the role of 18 F-FDG PET/CT for staging, neoadjuvant chemotherapy response evaluation, and final outcome assessment in International Retinoblastoma Staging System (IRSS) stage III retinoblastoma. Methods: Twenty-five consecutive IRSS stage III patients, with a median age of 3 y, were prospectively enrolled after ethics approval. All patients received neoadjuvant chemotherapy followed by enucleation, radiotherapy, and adjuvant chemotherapy. PET/CT was performed at baseline (PET/CT-1) and after 3 cycles of neoadjuvant chemotherapy (PET/CT-2). All 25 patients underwent PET/CT-1, and 21 of 25 patients underwent PET/CT-2. PET/CT-1 was compared with routine staging, and response on PET/CT-2 was assessed by criteria from the European Organization for Research and Treatment of Cancer response. Eventfree survival (EFS) and overall survival (OS) were calculated using Kaplan-Meier survival analysis, and differences between the groups were compared using log-rank test. A P value of 0.05 or less was considered significant. Results: Increased 18 F-FDG uptake was noted in primary extraocular tumor in all patients, except 5 with bilateral retinoblastoma (one eye with advanced and the other eye with intraocular disease) in whom the intraocular tumor did not show 18 F-FDG uptake. Five of 22 IRSS stage IIIA patients with clinically negative cervical lymph node involvement were found to have uptake in cervical lymph nodes on PET/CT-1, and 2 of 3 IRSS stage IIIB patients with pathologically confirmed cervical lymph node involvement did not show any uptake in the involved lymph nodes. No significant difference in EFS and OS was seen between IRSS stage IIIA and IIIB patients using routine staging or PET/CT staging (P $ 0.05); however, there was a trend toward better OS in patients with IRSS stage IIIB disease on PET/CT (P 5 0.065). There was no significant discordance between routine staging and PET/CT staging (P 5 0.256). The 8 patients with optic nerve uptake had lower EFS (P 5 0.0001) and OS (P 5 0.0009) than did 17 patients without optic nerve uptake on PET/CT-1. The 17 patients with complete response or partial response had better EFS (P 5 0.042) and OS (P 5 0.026) than did the 4 patients with progressive disease on PET/CT-2. Conclusion: Optic nerve uptake at baseline on PET/CT and response after neoadjuvant chemotherapy according to criteria from the European Organization for Research and Treatment of Cancer are strong predictors of EFS and OS in IRSS stage III retinoblastoma.

show abstract

Section: Discussionmentioning

confidence: 80%

mentioning

confidence: 99%

Role of PET/CT in Staging and Evaluation of Treatment Response After 3 Cycles of Chemotherapy in Locally Advanced Retinoblastoma: A Prospective Study

Radhakrishnan¹,

Kumar²,

Malhotra³

et al. 2012

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…In ophthalmology, there has been interest in the use of PET/CT for screening, staging, and follow-up evaluations for patients with choroidal melanoma, ocular adnexal lymphoma, metastatic carcinoma, conjunctival melanoma, retinoblastoma, and sarcoidosis (7)(8)(9)(10)(19)(20)(21). Furthermore, PET/CT standardized uptake values (SUV) have been evaluated as a biomarker for metastatic choroidal melanoma (22,23).…”

Section: Introductionmentioning

confidence: 99%

[18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) Physiologic Imaging of Choroidal Melanoma: Before and After Ophthalmic Plaque Radiation Therapy

Finger¹,

Chin²

2011

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…25 This neuroimaging modality has found a great use in the functional evaluation of malignant tumors of the eye (malignant melanoma of the choroid, retinoblastoma, metastatic disease, and lymphomas) and brain tumors including pituitary tumors. 12,26,34,39 Visual and oculomotor changes are known to occur following a stroke. The oculomotor repair during the period just after a stroke has been studied using PET.…”

Section: Positron Emission Tomography and Spectmentioning

confidence: 99%

Neuroimaging in neuroophthalmology

Bose¹

2007

FOC

View full text Add to dashboard Cite

✓Recent advancements in the speed and accuracy of data acquisition and resolution of neuroimaging and interventional techniques have revolutionized the early anatomical and functional diagnosis, prognosis, and treatment of many neuroophthalmological disorders. The relatively new techniques include magnetic resonance (MR) spectroscopy, computed tomography angiography, positron emission tomography, and functional MR imaging. In this paper the author describes the principles of the current techniques used by neuroophthalmologists and their value in the diagnosis, localization, and treatment of various afferent and efferent visual and ocular disorders.

show abstract

Fluorine-18 fluorodeoxyglucose positron emission tomography (PET) to detect vital retinoblastoma in the eye: Preliminary experience

Abstract: Based on this small pilot study, F18-PET shows little promise in the detection of retinoblastoma. More research on other radiofarmacons is recommended.

Cited by 24 publications

References 4 publications

Role of PET/CT in Staging and Evaluation of Treatment Response After 3 Cycles of Chemotherapy in Locally Advanced Retinoblastoma: A Prospective Study

Role of PET/CT in Staging and Evaluation of Treatment Response After 3 Cycles of Chemotherapy in Locally Advanced Retinoblastoma: A Prospective Study

[18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) Physiologic Imaging of Choroidal Melanoma: Before and After Ophthalmic Plaque Radiation Therapy

Neuroimaging in neuroophthalmology

Contact Info

Product

Resources

About